1. The press conference will be held at 3 PM on September 22.
Comment: Many experts have similar expectations for this press conference as for September 24, 2024; I believe they cannot be compared, mainly for three reasons:
First, the index levels are different; it was 2700 points at that time, now it's 3800 points; there was a liquidity crisis, now there's over 2 trillion in trading volume every day, and the market is very active; at that time, the aim was to rescue the market, now there's no desire to let it go too crazy;
Second, the market sentiment and participation are different; at that time, no one was talking about the stock market, and there were more comments about stopping losses and not entering the market; now both domestic investors, retail investors, and foreign investors are relatively optimistic;
Now it is common to call 4000 points, and there are also quite a few calling for 4500;
In summary, this meeting is more about introducing past achievements, stabilizing the market is good enough, and there should not be overly high expectations.
2. Moole Technology's Sci-Tech Innovation Board IPO will be held on September 26, known as the 'Eastern NVIDIA' GPU; the AI intelligent computing business dominates with over 80% market share; it has redefined the secondary market's evaluation standards for technology companies with 'three consecutive years of losses but revenue growth exceeding 200%.' Nearly 5 billion in R&D investment in the last three years;
Evaluation: Regardless of how it's said, it's a positive for technology. The key is its pricing after listing; if the increase is huge, it will stimulate the already listed tech companies;
However, many beneficiary stocks of the Moole concept have seen significant short-term gains, so be mentally prepared for the peak after the good news is realized. Trading is a game of human nature; when everyone is consistently bullish, it often means risk is approaching.
Over the weekend, many experts have listed a bunch of beneficiary stocks; when experts are overly excited, we need to be cautious;
3. The 11th batch of drug procurement first proposed 'anti-involution' to adjust the direction of 'only low prices.'
Evaluation: This is beneficial for pharmaceutical stocks, especially innovative drugs.
4. Financial fraud! Three companies will be ST next week.
Evaluation: Stay away from these companies with financial issues; the regulatory authorities have clearly stated their zero-tolerance attitude towards financial fraud, and the only thing we retail investors can do is to avoid them.
Specifically, how to avoid can be seen from some financial indicators, such as the debt-to-asset ratio; detailed analysis will be shared in our live broadcast later.
5. GC Meeting: Research on implementing domestic product standards and related policies in government procurement.
Evaluation: In the future, Chinese manufacturing and Chinese creativity need to enter the Chinese market according to our standards; this reflects the requirements of 'substantive production' and 'key technology autonomy and controllability';
Improve the government procurement system, regulate market order, implement national treatment, optimize the business environment, support industrial upgrading, enhance supply chain resilience, align with international rules, and participate in global cooperation; clarify the definition of 'domestic products' to regulate government procurement behavior; support domestic industry development by providing price discounts; optimize the business environment by treating domestic and foreign capital equally. The implementation of this policy will inject new vitality into our government procurement market and promote high-quality economic development.
Summary: The overall news over the weekend is generally positive, especially the press conference on Monday, where the market has certain expectations, positively impacting the A-share trend on Monday; the technology sector continues to benefit.
Statement: Personal opinion for reference only; trade at your own risk!
